Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
Completed
- Conditions
- Covid19
- Registration Number
- NCT04829552
- Lead Sponsor
- William Beaumont Hospitals
- Brief Summary
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 704
Inclusion Criteria
- Age >18 years old
- positive reverse transcription-polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens.
- Intensive care unit (ICU) patient or Step-down unit (SDU) patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.
- peak d-dimer levels exceeding 1,000 mcg/mL at any time during admission.
Exclusion Criteria
- Hospital length of stay less than 5 days.
- Hemorrhage before ICU/SDU admission.
- Treatment with an anticoagulant other than low molecular weight heparin or unfractionated heparin.
- Constant treatment with the same dose of anticoagulant for less than 5 days.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inpatient all-cause mortality During hospitalization, up to 6 months
- Secondary Outcome Measures
Name Time Method Rates of major bleeding events During hospitalization, up to 6 months as defined by the International Society on Thrombosis and Hemostasis
Rates of venous thromboses During hospitalization, up to 6 months Intensive care unit/Step down unit length of stay During hospitalization, up to 6 months
Trial Locations
- Locations (1)
Beaumont Health System (BHS)
🇺🇸Royal Oak, Michigan, United States
Beaumont Health System (BHS)🇺🇸Royal Oak, Michigan, United States